In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography

被引：74

作者：

Aboagye, EO ^{[1
]}

Price, PM ^{[1
]}

Jones, T ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp,Sch Med, MRC Cycltron Unit, PET Oncol Grp,Dept Canc Med, London W12 0NN, England

来源：

DRUG DISCOVERY TODAY | 2001年 / 6卷 / 06期

关键词：

D O I：

10.1016/S1359-6446(01)01684-1

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Positron-emission tomography (PET) is a sensitive technique that can be used to measure drug pharmacokinetics and pharmacodynamics noninvasively in target tissues of patients. Here we focus on the application of this technology to address some of the bottlenecks in drug development, including: elucidation of pathophysiology: evaluation of pharmacokinetics, proof of principle of mechanism, and assessment of efficacy and/or response to therapy.

引用

页码：293 / 302

页数：10

共 48 条

[1]

Aloj L, 1999, CANCER RES, V59, P4709

[2]

ANDERSON H, 2000, P AN M AM SOC CLIN, V19, pA179

[3] POTENTIAL ANTITUMOR AGENTS .50. INVIVO SOLID-TUMOR ACTIVITY OF DERIVATIVES OF N-[2-(DIMETHYLAMINO)ETHYL]ACRIDINE-4-CARBOXAMIDE [J].

ATWELL, GJ ;

REWCASTLE, GW ;

BAGULEY, BC ;

DENNY, WA .

JOURNAL OF MEDICINAL CHEMISTRY, 1987, 30 (04) :664-669

[4] Metabolic imaging using F18-fluorodeoxyglucose to assess myocardial viability [J].

Bax, JJ ;

Visser, FC ;

vanLingen, A ;

Cornel, JH ;

Fioretti, PM ;

vanderWall, EE .

INTERNATIONAL JOURNAL OF CARDIAC IMAGING, 1997, 13 (02) :145-155

[5] DOSE-DEPENDENT OCCUPANCY OF CENTRAL DOPAMINE-D(2) RECEPTORS BY THE NOVEL NEUROLEPTIC CP-88,059-01 - A STUDY USING POSITRON EMISSION TOMOGRAPHY AND C-11 RACLOPRIDE [J].

BENCH, CJ ;

LAMMERTSMA, AA ;

DOLAN, RJ ;

GRASBY, PM ;

WARRINGTON, SJ ;

GUNN, K ;

CUDDIGAN, M ;

TURTON, DJ ;

OSMAN, S ;

FRACKOWIAK, RSJ .

PSYCHOPHARMACOLOGY, 1993, 112 (2-3) :308-314

[6] The time course of binding to striatal dopamine D-2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography [J].

Bench, CJ ;

Lammertsma, AA ;

Grasby, PM ;

Dolan, RJ ;

Warrington, SJ ;

Boyce, M ;

Gunn, KP ;

Brannick, LY ;

Frackowiak, RSJ .

PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :141-147

[7]

Brock CS, 2000, BRIT J CANCER, V82, P608

[8] Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology? [J].

Brock, CS ;

Meikle, SR ;

Price, P .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1997, 24 (06) :691-705

[9]

BROCK CS, 1996, P AN M AM SOC CLIN, V15, P475

[10]

Brown G. D., 1994, Journal of Labelled Compounds and Radiopharmaceuticals, V35, P100

← 1 2 3 4 5 →